Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400
Recruiting · Phase 1 · NCT06084481
Conditions: Hepatocellular Carcinoma, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancers, Esophageal Squamous Cell Carcinoma, Triple Negative Breast Cancer, Hormone Receptor+/Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer, Head and Neck Squamous-Cell Carcinoma, Platinum Resistant High Grade Epithelial Ovarian Cancer
At a glance
- Research payments reported, 2025
- $4.3M
- U.S. investigators named
- 24
- Sites paid
- 21
- Planned or actual enrollment
- 325
About the trial
- Sponsor
- AbbVie
- Tested
- ABBV-400 (drug), Itraconazole (ITZ) (drug), Bevacizumab (drug)
- Dates
- Started 2023-11-09; completion 2027-09
- Results posted
- Not yet
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess adverse events and change in disease activity when ABBV-400 is given to adult participants to treat advanced solid tumors. ABBV-400 is an investigational drug being developed for the treatment of advanced solid tumors. Study doctors put the participants in groups called cohorts. Cohorts 1-8 receive ABBV-400 alone (monotherapy), cohort 9 receives ABBV-400 with a strong CYP3A3 inhibitor (ITZ), and cohort 10 receives ABBV-400 with bevacizumab. All cohorts are followed by a safety follow-up period. Approximately 325 adult participants with hepatocellular carci…
From ClinicalTrials.gov, last updated 2026-10-14. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $4.3M in research payments for this study in 2025 (1,811 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Pamela N. Munster, MD Medical Oncology · Stanford, CA
- Yan Xing, MD Medical Oncology · Duarte, CA
- Jason Henry, M.D Internal Medicine · Denver, CO
- Jessica D. Mcdermott, M.D. Medical Oncology · Denver, CO
- Manish R. Patel, MD Medical Oncology · Sarasota, FL
- John H. Strickler, MD Hematology & Oncology · Jacksonville, FL
- Chih-yi Liao Hematology & Oncology · Chicago, IL
- Devalingam Mahalingam, M.D. Medical Oncology · Chicago, IL
- Victorine V. Muse, MD Radiology · Boston, MA
- Danielle M. Richman, M.D., M.S. Radiology · Boston, MA
- Manish Sharma, M.D. Medical Oncology · Grand Rapids, MI
- Amit Mahipal Medical Oncology · Rochester, MN
- Andrew A. Davis, MD Medical Oncology · Florissant, MO
- Kevin S. Baker, MD Radiology · Stony Brook, NY
- James Harding, MD Hematology & Oncology · New York, NY
- Maria V. Garcia Pallas, M.D. Hematology & Oncology · Guaynabo, PR
- Alexander G. Raufi, M.D. Hematology & Oncology · Providence, RI
- William J. Edenfield, MD Medical Oncology · Greenville, SC
- Albert Lockhart, MD Medical Oncology · Charleston, SC
- Meredith S. Pelster, M.D. Hematology & Oncology · Nashville, TN
- David S. Hong, M.D. Medical Oncology · Houston, TX
- Daruka Mahadevan, MD, PHD Medical Oncology · San Antonio, TX
- Kyriakos P. Papadopoulos, M.D. Hematology & Oncology · San Antonio, TX
- Raymond C. Wadlow, MD Hematology & Oncology · Fairfax, VA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Start Midwest LLC $681,634
- Duke University $574,769
- Uh Cleveland Medical Center, OH $429,056
- Sarah Cannon Research Institute LLC $385,520
- Rhode Island Hospital, RI $354,511
- UCSF Langley Porter Psychiatric Hospital and Clinics, CA $262,678
- Northwestern University $259,823
- The University of Texas Health Science Center at San Antonio $236,379
- South Texas Accelerated Research Therapeutics $187,142
- City of Hope National Medical Ctr $179,464
- Memorial Sloan Kettering Cancer Center $171,982
- University of Chicago $162,885
- Washington University $110,057
- Ut MD Anderson Cancer Center $77,981
- Inova Fairfax Hospital, VA $69,280
- Medical University of South Carolina $54,422
- Pan American Center for Oncology Trials LLC $41,023
- Prisma Health Greenville Memorial Hospital, SC $34,875
- Regents of the University of Colorado $8,294
- Sbq Radiology PLLC $4,800
- Start San Antonio LLC $2,728
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.